| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Adaptimmune Therapeutics PLC Sponsored ADR$0.05
-0.01 (-17.57%)
D 39Pipeline Score Fair Value Biotech · Clinical
Market Cap
17.15 M
EPS
-0.66
P/E Ratio
-
Value Trade
3.17 M
-19.32 %
Week
-58.72 %
1 Month
-54.25 %
3 Month
-78.87 %
6 Month
-98.85 %
5 Year
-99.71 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
50.78 M
52 Week Range
0.04 - 0.86
% held by Insiders
11.33 %
% held by Institutions
34.07 %
Enterprise Value
39.77 M
Total Shares
265.05 M
Short %
2 %
Float Shares
255.41 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D39
Pipeline Score $35M
Pipeline ValueFair Value
Valuation Signal6
Drugs Scored2.1x
rNPV / MCap Top 55%
Micro Cap (rank 409 of 906)
Percentile RankAdaptimmune Therapeutics PLC Sponsored ADR faces pipeline headwinds (39/100), with $2.8B risk-adjusted pipeline value, led by WT-gag-TCR modified T cells in HIV Infections (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WT-gag-TCR modified T cells Monoclonal antibody | HIV Infections | Phase 1 | NCT00991224 | 43% | $2.4B | COMPLETED | 2 | - | - | Jan 1, 2014 | - | Oct 10, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
lete-cel | advanced or metastatic synovial sarcoma or MRCLS | Phase 2 | 2024-11-13 | overall response rate: 42%; complete responses: 6/64; partial responses: 21/64; response rate synovial sarcoma: 41%; response rate MRCLS: 43%; median duration of response: 12.2 months; median duration of response synovial sarcoma: 18.3 months Read More | Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial 42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); tw Read More | |
lete-cel | advanced or metastatic synovial sarcoma or MRCLS | Phase 2 | 2024-11-13 | overall response rate: 42%; complete responses: 6/64; partial responses: 21/64; response rate synovial sarcoma: 41%; response rate MRCLS: 43%; median duration of response: 12.2 months; median duration of response synovial sarcoma: 18.3 months Read More | Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial 42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); tw Read More | |
lete-cel | advanced or metastatic synovial sarcoma or MRCLS | Phase 2 | 2024-11-13 | overall response rate: 42%; complete responses: 6/64; partial responses: 21/64; response rate synovial sarcoma: 41%; response rate MRCLS: 43%; median duration of response: 12.2 months; median duration of response synovial sarcoma: 18.3 months Read More | Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial 42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); tw Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ADAP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ADAP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ADAP ranks across every disease it competes inCompetitive Position is a premium feature
See how ADAP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial